Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gastroenterology

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2008.10.049PMID 19084016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

  2008cited by this paper
• Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

  2007cited by this paper
• HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long‐term follow‐up

  2007cited by this paper
• Grading and staging systems for inflammation and fibrosis in chronic liver diseases.

  2007cited by this paper
• Molecular diagnostics of hepatitis C virus infection: a systematic review.

  2007cited by this paper
• Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

  2007cited by this paper
• Occult HBV infection may represent a major risk factor of non‐response to antiviral therapy of chronic hepatitis C

  2007cited by this paper
• Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan

  2007cited by this paper
• Virological Profiles in Hepatitis B Virus/Hepatitis C Virus Coinfected Patients under Interferon plus Ribavirin Therapy

  2006cited by this paper
• A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

  2006cited by this paper
• Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.

  2006cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection

  2005cited by this paper
• Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy

  2005cited by this paper
• Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections.

  2005cited by this paper
• Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan

  2005cited by this paper
• Influence of Chronic Coinfection with Hepatitis B and C Virus on Liver Histology

  2004cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004cited by this paper
• A forgotten population with chronic hepatitis C infection: Subjects coinfected with hepatitis B virus

  2004cited by this paper
• Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis.

  2004cited by this paper
• Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

  2003cited by this paper
• A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with Α-interferon and ribavirin

  2003cited by this paper
• Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan.

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course

  2002cited by this paper
• High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.

  2001cited by this paper
• High Doses of α-Interferon Are Required in Chronic Hepatitis Due to Coinfection With Hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial

  2001cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis

  2000cited by this paper
• Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.

  1999cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

  1998cited by this paper
• Response of Patients with Dual Hepatitis B Virus and C Virus Infection to Interferon Therapy

  1997cited by this paper
• Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection

  1997cited by this paper
• Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

  1996cited by this paper
• Role of hepatitis C virus in dual and triple hepatitis virus infection

  1995cited by this paper
• Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience.

  1990cited by this paper
• Designing Clinical Research: An Epidemiologic Approach

  1988cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Evolution of qHBsAg levels in HBV/HCV co-infected patients with low serum HBV DNA: Comparison between treated versus untreated.

  2025cites this paper
• Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Plant Systems as Platforms for the Production of Interferon Alpha and its Application

  2025cites this paper
• HBV DNA integration and somatic mutations in HCC patients with HBV-HCV dual infection reveals profiles intermediate between HBV- and HCV-related HCC

  2025cites this paper
• Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

  2023cites this paper
• The art of managing hepatitis C virus in special population groups: a paradigm shift

  2022cites this paper
• A Biotechnological Approach for the Production of Pharmaceutically Active Human Interferon-α from Raphanus sativus L. Plants

  2022cites this paper
• Addressing Hepatitis B in the Context of Hepatitis C

  2021cites this paper
• Treatment of HCV, HDV, or HIV Coinfections

  2021cites this paper
• Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV

  2021cites this paper
• Occult Hepatitis B Infection

  2021cites this paper
• Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection.

  2021cites this paper
• Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

  2021cites this paper
• Entecavir prevents HBV reactivation during direct acting antivirals for HCV/HBV dual infection: a randomized trial.

  2021cites this paper
• The endoplasmic reticulum unfolded protein response – homeostasis, cell death and evolution in virus infections

  2021cites this paper
• Recent advancements in the genetic engineering of microalgae

  2021cites this paper
• Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

  2021cites this paper
• Title : Viral interference between dengue virus and hepatitis C virus infections Short running title : Interference between DENV and HCV

  2020cites this paper
• Viral Interference Between Dengue Virus and Hepatitis C Virus Infections

  2020cites this paper
• Hepatitis C Virus and Hepatitis B Virus Co-Infection

  2020cites this paper
• Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)

  2020cites this paper
• Hepatitis B virus reactivation while on hepatitis C virus direct‐acting antiviral therapy: is that a real concern and when is it a concern?

  2020cites this paper
• Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.

  2020cites this paper
• Hepatitis C and hepatitis B coinfection

  2020cites this paper
• Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)

  2019cites this paper
• Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore

  2019cites this paper
• Treatment of Hepatitis C Virus in Special Populations (HBV Coinfection, Drug Users, and Prisoners)

  2019cites this paper
• Taiwan consensus statement on the management of chronic hepatitis B.

  2019cites this paper
• Updates in the management of hepatitis B in children

  2019cites this paper
• HBV Reactivation during Direct-Acting Antiviral Therapy in Hepatitis B and C Coinfected Patients Undergoing Haemodialysis

  2019cites this paper
• Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives

  2019cites this paper
• Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives

  2019cites this paper
• Implementation of Treating Chronic Hepatitis C in a Correcting Institute by a Hospital-Backup Clinic

  2018cites this paper
• Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C

  2018cites this paper
• Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients

  2018cites this paper
• Impact of etiological treatment on prognosis

  2018cites this paper
• Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues

  2018cites this paper
• Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

  2018cites this paper
• Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.

  2018cites this paper
• 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

  2018cites this paper
• Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

  2018cites this paper
• HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation

  2018influential citation
• Hepatitis B and C Coinfection

  2018cites this paper
• A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort

  2018cites this paper
• Engineering Chlamydomonas reinhardtii for Expression of Functionally Active Human Interferon-α

  2018cites this paper
• A real world cost effectiveness analysis of interferon‐based therapy for HCV naïve super‐responders

  2018cites this paper
• Treatment of HCV, HDV, or HIV Coinfection

  2018cites this paper
• HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals

  2018cites this paper
• Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.

  2018cites this paper
• Hepatitis B

  2018cites this paper
• Profile and value of FIB‐4 in patients with dual chronic hepatitis C and B

  2018cites this paper
• Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

  2018cites this paper
• Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.

  2017cites this paper
• Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals

  2017cites this paper
• Chronic Hepatitis B Reactivation Subsequent to Chronic Hepatitis C Treatment: A Case Report

  2017cites this paper
• An update on the treatment options for HBV/HCV coinfection

  2017cites this paper
• Interferon‐Free Regimens in Hepatitis B Surface Antigen/Anti–Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation

  2017cites this paper
• Title : Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals Short title : HBV reactivation in DAA therapy Authorship

  2017cites this paper
• Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.

  2017cites this paper
• Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.

  2017cites this paper
• Letter: HBV/HCV coinfection in the era of direct‐acting antivirals

  2017cites this paper
• HEPATITIS C VIRUS GENOTYPE DISTRIBUTION AMONGST HCV POSITIVE PATIENTS PRESENTING AT A PRIVATE TERTIARY CARE HOSPITAL OF PESHAWAR, KHYBER PAKHTUNKHWA

  2017cites this paper
• Spontaneous remission of hepatitis B virus reactivation during direct‐acting antiviral agent‐based therapy for chronic hepatitis C

  2017cites this paper
• No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct‐acting antivirals for hepatitis C in a large real‐world cohort

  2017cites this paper
• Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis

  2017influential citation
• Treating Chronic Hepatitis C with Pegylated Interferon and Ribavirin Between the Incarcerated and the Community Patients

  2017cites this paper
• COINFECTION WITH HEPATITIS B AND HEPATITIS C VIRUS: NEW INSIGHTS OF TREATMENT IN THE ERA OF DIRECT ACTING ANTIVIRALS.

  2017cites this paper
• Comparing the risk of hepatitis B virus reactivation between direct‐acting antiviral therapies and interferon‐based therapies for hepatitis C

  2017cites this paper
• Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.

  2017cites this paper
• Hepatitis B Virus and Hepatitis C Virus Co-infection: An Evaluation of Eighty-Two Patients

  2017cites this paper
• APASL consensus statements and recommendation on treatment of hepatitis C

  2016cites this paper
• MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin

  2016cites this paper
• KASL clinical practice guidelines: management of chronic hepatitis B

  2016cites this paper
• KASL clinical practice guidelines: management of hepatitis C

  2016cites this paper
• Reactivation of hepatitis B virus during interferon‐free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co‐infection

  2016cites this paper
• HEPATITIS C VIRUS GENOTYPES IN PATIENTS REFERRED TO EDUCATIONAL HOSPITALS IN ZAHEDAN (2009-2013)

  2016cites this paper
• Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus

  2016cites this paper
• Simple predictor for anemia in chronic hepatitis C patients receiving peginterferon plus ribavirin

  2016cites this paper
• From current status to optimization of HCV treatment: Recommendations from an expert panel.

  2016cites this paper
• Perspectives on dual hepatitis B and C infection in Taiwan.

  2016cites this paper
• Long‐term efficacy of Peg‐Interferon/Ribavirin with and without Lamivudine therapy for HBeAg‐positive hepatitis B and C dual infection

  2016cites this paper
• New hepatitis C therapies for special patient populations

  2016cites this paper
• ペグインターフェロン，リバビリン，シメプレビル3剤併用療法にてC型肝炎ウイルスに対して著効が得られるも，HBV DNA量の増加を来したB型C型重複感染の1例

  2015cites this paper
• The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management

  2015influential citation
• Effect of Previous Exposure to HBV on Liver Histology and Treatment Response in CHC Patients.

  2015cites this paper
• Optimal management of patients with chronic hepatitis C and comorbidities

  2015cites this paper
• Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection.

  2015cites this paper
• Recommendations for the management of hepatitis C virus infection among people who inject drugs.

  2015cites this paper
• Hepatitis-C-Koinfektionen

  2015cites this paper
• Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

  2015cites this paper
• MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

  2015cites this paper
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

  2015cites this paper
• Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

  2015cites this paper
• Genotype 3 is the predominant hepatitis C genotype in a multi-ethnic Asian population in Malaysia.

  2015cites this paper
• Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.

  2015cites this paper
• Emerging Challenges in Managing Hepatitis B in HIV Patients

  2015cites this paper
• Impact of occult hepatitis B virus infection on antiviral therapy in chronic hepatitis C patients

  2015cites this paper
• Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin

  2015cites this paper
• Management of chronic hepatitis B in patients from special populations.

  2015cites this paper